These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9310805)

  • 1. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH).
    van der Werf TS; Mulder PO; Zijlstra JG; Uges DR; Stegeman CA
    Intensive Care Med; 1997 Aug; 23(8):873-7. PubMed ID: 9310805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure.
    Valtonen M; Tiula E; Takkunen O; Backman JT; Neuvonen PJ
    J Antimicrob Chemother; 2001 Dec; 48(6):881-5. PubMed ID: 11733473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
    Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
    Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of intraperitoneal piperacillin/tazobactam in patients on peritoneal dialysis with and without pseudomonas peritonitis.
    Zaidenstein R; Weissgarten J; Dishi V; Koren M; Soback S; Gips M; Averbuch Z; Simantov R; Assulin E; Golik A
    Perit Dial Int; 2000; 20(2):227-31. PubMed ID: 10809248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drastic reduction of piperacillin-tazobactam concentrations in an in-vitro model of continuous venovenous hemofiltration: proposal of an innovative modality of administration to maintain them at constant concentration.
    Ferrannini M; Niscola P; Falcone C; Noce A; Pastore A; Di Giovamberardino G; Tendas A; Scaramucci L; Di Daniele N; Palumbo R
    Cardiovasc Hematol Agents Med Chem; 2013 Sep; 11(3):187-93. PubMed ID: 23547902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration.
    Capellier G; Cornette C; Boillot A; Guinchard C; Jacques T; Blasco G; Barale F
    Crit Care Med; 1998 Jan; 26(1):88-91. PubMed ID: 9428548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
    Kim MK; Capitano B; Mattoes HM; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2002 May; 22(5):569-77. PubMed ID: 12013355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment.
    Murao N; Ohge H; Ikawa K; Watadani Y; Uegami S; Shigemoto N; Shimada N; Yano R; Kajihara T; Uemura K; Murakami Y; Morikawa N; Sueda T
    Int J Antimicrob Agents; 2017 Sep; 50(3):393-398. PubMed ID: 28694230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
    Varghese JM; Jarrett P; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment.
    Derendorf H; Dalla Costa T
    Int J Clin Pharmacol Ther; 1996 Nov; 34(11):482-8. PubMed ID: 8937930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations.
    Dalla Costa T; Nolting A; Rand K; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):426-33. PubMed ID: 9352391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections.
    Chen R; Qian Q; Sun MR; Qian CY; Zou SL; Wang ML; Wang LY
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):363-72. PubMed ID: 25894901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of levofloxacin in critically ill patients with renal failure: influence of continuous veno-venous hemofiltration.
    Bellmann R; Egger P; Gritsch W; Bellmann-Weiler R; Joannidis M; Dunzendorfer S; Wiedermann CJ
    Int J Clin Pharmacol Ther; 2002 Apr; 40(4):142-9. PubMed ID: 11996208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
    Yusuf E; Spapen H; Piérard D
    J Crit Care; 2014 Dec; 29(6):1089-95. PubMed ID: 25179412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment.
    Dowell JA; Korth-Bradley J; Milisci M; Tantillo K; Amorusi P; Tse S
    J Clin Pharmacol; 2001 Sep; 41(9):979-86. PubMed ID: 11549103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis.
    Tomaselli F; Dittrich P; Maier A; Woltsche M; Matzi V; Pinter J; Nuhsbaumer S; Pinter H; Smolle J; Smolle-Jüttner FM
    Br J Clin Pharmacol; 2003 Jun; 55(6):620-4. PubMed ID: 12814459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.
    Lister PD; Prevan AM; Sanders CC
    Antimicrob Agents Chemother; 1997 Apr; 41(4):721-7. PubMed ID: 9087477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients.
    Nau R; Kinzig-Schippers M; Sörgel F; Schinschke S; Rössing R; Müller C; Kolenda H; Prange HW
    Antimicrob Agents Chemother; 1997 May; 41(5):987-91. PubMed ID: 9145857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cefpirome in critically ill patients with renal failure treated by continuous veno-venous hemofiltration.
    Van der Werf TS; Fijen JW; Van de Merbel NC; Spanjersberg R; Möller AV; Ligtenberg JJ; Tulleken JE; Zijlstra JG; Stegeman CA
    Intensive Care Med; 1999 Dec; 25(12):1427-31. PubMed ID: 10660852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
    J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.